404 related articles for article (PubMed ID: 25824235)
1. Reduced ADAMTS13 activity is associated with thrombotic risk in systemic lupus erythematosus.
Martin-Rodriguez S; Reverter JC; Tàssies D; Espinosa G; Heras M; Pino M; Escolar G; Diaz-Ricart M
Lupus; 2015 Oct; 24(11):1143-9. PubMed ID: 25824235
[TBL] [Abstract][Full Text] [Related]
2. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic microangiopathic hemolytic anemia with reduction of ADAMTS13 activity: initial manifestation of childhood-onset systemic lupus erythematosus.
Muscal E; Edwards RM; Kearney DL; Hicks JM; Myones BL; Teruya J
Am J Clin Pathol; 2011 Mar; 135(3):406-16. PubMed ID: 21350095
[TBL] [Abstract][Full Text] [Related]
4. [The association of von Willebrand factor and von Willebrand factor-cleaving protease in systemic lupus erythematosus].
Lu GY; Guo XF; Wang ZY; Bai X; Su J; Ruan CG
Zhonghua Nei Ke Za Zhi; 2006 Jan; 45(1):42-4. PubMed ID: 16624087
[TBL] [Abstract][Full Text] [Related]
5. [A study on the significance of plasma thrombospondin1 in thrombotic thrombocytopenic purpura and the relationship between thrombospondin1 and von Willebrand factor cleaving protease (ADAMTS13)].
Liu F; Lu GY; Dong NZ; Bai X; Su J; Ruan CG
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3190-3. PubMed ID: 16405838
[TBL] [Abstract][Full Text] [Related]
6. The potential therapeutic benefit of targeting ADAMTS13 activity.
Eerenberg ES; Levi M
Semin Thromb Hemost; 2014 Feb; 40(1):28-33. PubMed ID: 24338607
[TBL] [Abstract][Full Text] [Related]
7. The role of ADAMTS13 in the pathogenesis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
George JN
Clin Adv Hematol Oncol; 2005 Aug; 3(8):627-32. PubMed ID: 16167049
[TBL] [Abstract][Full Text] [Related]
8. Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension.
van den Born BJ; van der Hoeven NV; Groot E; Lenting PJ; Meijers JC; Levi M; van Montfrans GA
Hypertension; 2008 Apr; 51(4):862-6. PubMed ID: 18332284
[TBL] [Abstract][Full Text] [Related]
9. Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.
Budde U; Schneppenheim R
Hamostaseologie; 2014; 34(3):215-25. PubMed ID: 25010251
[TBL] [Abstract][Full Text] [Related]
10. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
[TBL] [Abstract][Full Text] [Related]
11. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.
Schwameis M; Schörgenhofer C; Assinger A; Steiner MM; Jilma B
Thromb Haemost; 2015 Apr; 113(4):708-18. PubMed ID: 25503977
[TBL] [Abstract][Full Text] [Related]
12. Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases.
Habe K; Wada H; Ito-Habe N; Hatada T; Matsumoto T; Ohishi K; Maruyama K; Imai H; Mizutani H; Nobori T
Thromb Res; 2012 May; 129(5):598-602. PubMed ID: 22070827
[TBL] [Abstract][Full Text] [Related]
13. Plasma ADAMTS13, von Willebrand Factor (VWF), and VWF Propeptide Profiles in Patients With Connective Tissue Diseases and Antiphospholipid Syndrome.
Habe K; Wada H; Matsumoto T; Ohishi K; Ikejiri M; Tsuda K; Kondo M; Kamimoto Y; Ikeda T; Katayama N; Mizutani H
Clin Appl Thromb Hemost; 2017 Sep; 23(6):622-630. PubMed ID: 26759371
[TBL] [Abstract][Full Text] [Related]
14. Occurrence of thrombotic thrombocytopenic purpura in a systemic lupus erythematosus patient with antiphospholipid antibodies in association with a decreased activity of von Willebrand factor-cleaving protease.
Matsuda J; Sanaka T; Gohchi K; Matsui K; Uchida S; Matsumoto M; Fujimura Y
Lupus; 2002; 11(7):463-4. PubMed ID: 12195790
[No Abstract] [Full Text] [Related]
15. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis).
Mannucci PM; Vanoli M; Forza I; Canciani MT; Scorza R
Haematologica; 2003 Aug; 88(8):914-8. PubMed ID: 12935979
[TBL] [Abstract][Full Text] [Related]
16. The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction.
Austin SK; Starke RD; Lawrie AS; Cohen H; Machin SJ; Mackie IJ
Br J Haematol; 2008 May; 141(4):536-44. PubMed ID: 18341632
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases.
Matsuyama T; Kuwana M; Matsumoto M; Isonishi A; Inokuma S; Fujimura Y
Thromb Haemost; 2009 Aug; 102(2):371-8. PubMed ID: 19652889
[TBL] [Abstract][Full Text] [Related]
18. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
Tersteeg C; de Maat S; De Meyer SF; Smeets MW; Barendrecht AD; Roest M; Pasterkamp G; Fijnheer R; Vanhoorelbeke K; de Groot PG; Maas C
Circulation; 2014 Mar; 129(12):1320-31. PubMed ID: 24449821
[TBL] [Abstract][Full Text] [Related]
19. Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation.
Peyvandi F; Siboni SM; Lambertenghi Deliliers D; Lavoretano S; De Fazio N; Moroni B; Lambertenghi Deliliers G; Mannuccio Mannucci P
Br J Haematol; 2006 Jul; 134(2):187-95. PubMed ID: 16846477
[TBL] [Abstract][Full Text] [Related]
20. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Furlan M; Robles R; Galbusera M; Remuzzi G; Kyrle PA; Brenner B; Krause M; Scharrer I; Aumann V; Mittler U; Solenthaler M; Lämmle B
N Engl J Med; 1998 Nov; 339(22):1578-84. PubMed ID: 9828245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
